Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

NCT00692640 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Non-small Cell Lung Cancer

Interventions

DRUG: XL147 (SAR245408)
DRUG: Erlotinib

Sponsor

Sanofi